Abstract: An immunosuppressive agent which is very effective for treating autoimmune disease, inflammatory reaction, fibrosis or dysfunction caused by autoimmune disease and related disease thereof with tissue injury or infection rejection of transplantation, graft versus host disease by bone marrow (hematopoietic stem cell) transplantation, or allergic disease, by selectively inhibiting the activated T cells, is provided.

Abstract: An immunosuppressive agent which is very effective for treating autoimmune disease, inflammatory reaction, fibrosis or dysfunction caused by autoimmune disease and related disease thereof with tissue injury or infection, rejection of transplantation, graft versus host disease by bone marrow (hematopoietic stem cell) transplantation, or allergic disease, by selectively inhibiting the activated T cells, is provided.

Abstract: An immunosuppressive agent which is very effective for treating autoimmune disease, inflammatory reaction, fibrosis or dysfunction caused by autoimmune disease and related disease thereof with tissue injury or infection, rejection of transplantation, graft versus host disease by bone marrow (hematopoietic stem cell) transplantation, or allergic disease, by selectively inhibiting the activated T cells, is provided.

Abstract: There are disclosed amino acid derivatives represented by the following general formula (I): ##STR1## wherein L.sup.1 and L.sup.2 represent an amino acid residue etc., A.sup.1 and A.sup.3 represent C.dbd.O, A.sup.2 represents an alkylene group etc., m and n represent an integer of 1 to 5, V represents --NHC(.dbd.NH)NH.sub.2 etc., W represents --COOH etc., R.sup.1 and R.sup.2 represent hydrogen atom, alkyl group etc., R.sup.3 and R.sup.4 represent hydrogen etc. and X and Y represent --NH-- or --O-- and pharmaceutically acceptable salts thereof and agents for inhibiting tumor matastasis containing the compounds, and the amino acid derivatives exhibit high activity for inhibiting tumor metastasis and weak platelet aggregation inhibition activity and weak anticoagulation activity.

Abstract: A peptide derivative containing 1 to 20 units of peptide unit represented by the following general formula [I] or a pharmaceutically acceptable salt thereof;[Z]--Arg--X--Asp--[Y] [I]wherein Arg represents L- or D-arginine residue, Asp represents L-aspartic acid residue, X represents L- or D-leucine, D-isoleucine, L- or D-norleucine, L- or D-phenylalanine, D-phenylglycine or D-alanine residue, and [Z] and [Y] each represents an amino acid or a peptide residue, which may be present or absent, selected from glycine, L-serine, L-threonine, L- and D-aspartic acid, L-alanine, L- and D-glutamic acid, L-proline residues and a peptide residue constituted by the foregoing amino acid residues, and a pharmaceutical composition comprising the peptide derivative. The composition of the present invention is useful as an agent for inhibiting tumor metastasis.

Abstract: A polypeptide comprising repeated amino acid sequences of a cell-adhesive protein represented by the formula:(Arg-Gly-Asp)n or (Tyr-Ile-Gly-Ser-Arg)nwherein n is a number ranging from 2 to 20; or a pharmaceutical acceptable salt thereof, which is valuable as an antimetastatic agent for cancer.

Abstract: This invention relates to a functional polypeptide containing the binding domain of human fibronectin and the heparin-binding domain of human fibronectin.

Abstract: A polypeptide comprising repeated amino acid sequences of a cell-adhesive protein represented by the formula:(Arg--Gly--Asp)nor(Tyr--Ile--Gly--Ser--Arg)nwherein n is a number ranging from 2 to 20; or a pharmaceutical acceptable salt thereof, which is valuable as an antimetastatic agent for cancer.